Molecular structure of Apstatin, CAS Number: 160470-73-5
Apstatin (CAS 160470-73-5)
See product citations (2)
Alternate Names:
Aminopeptidase P Inhibitor; N-[(2S,3R)-3-Amino-2-hydroxy-4-phenylbutanoyl]-L-prolyl-L-prolyl-L-alaninamide
Application:
Apstatin is a selective inhibitor of Aminopeptidase P (APP)
CAS Number:
160470-73-5
Purity:
≥95%
Molecular Weight:
459.54
Molecular Formula:
C23H33N5O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Apstatin is a selective inhibitor of aminopeptidase P (APP), with a Ki of 2.6 muM in rat lung membrane-bound APP. Apstatin is shown to increase Bradykinin-promoted cardioprotection in rats with artificially introduced myocardial infarctions by inhibiting the Bradykinin degradation action of APP. When combined with the angiotensin-converting enzyme inhibitors enalapril (sc-205664), lisinopril (sc-205378), or ramipril (sc-205833), decrease of myocardial infarction size was enhanced.
Apstatin (CAS 160470-73-5) References
- Cardioprotective effects of the aminopeptidase P inhibitor apstatin: studies on ischemia/reperfusion injury in the isolated rat heart. | Erşahin, C., et al. 1999. J Cardiovasc Pharmacol. 34: 604-11. PMID: 10511138
- Effects of the aminopeptidase P inhibitor apstatin on bradykinin-induced inositol 1,4,5-triphosphate in neonatal rat cardiomyocytes. | Kudoh, A., et al. 2001. J Cardiovasc Pharmacol. 37: 495-501. PMID: 11336100
- Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway. | Wolfrum, S., et al. 2001. Br J Pharmacol. 134: 370-4. PMID: 11564655
- Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction. | Veeravalli, KK., et al. 2003. Pharmacol Res. 48: 557-63. PMID: 14527819
- Structure of Escherichia coli aminopeptidase P in complex with the inhibitor apstatin. | Graham, SC., et al. 2004. Acta Crystallogr D Biol Crystallogr. 60: 1770-9. PMID: 15388923
- Crystal structure of X-prolyl aminopeptidase from Caenorhabditis elegans: A cytosolic enzyme with a di-nuclear active site. | Iyer, S., et al. 2015. FEBS Open Bio. 5: 292-302. PMID: 25905034
- Structure of the human aminopeptidase XPNPEP3 and comparison of its in vitro activity with Icp55 orthologs: Insights into diverse cellular processes. | Singh, R., et al. 2017. J Biol Chem. 292: 10035-10047. PMID: 28476889
- Angiotensin-Converting Enzyme Inhibitor Protects Against Cisplatin Nephrotoxicity by Modulating Kinin B1 Receptor Expression and Aminopeptidase P Activity in Mice. | Estrela, GR., et al. 2020. Front Mol Biosci. 7: 96. PMID: 32528973
- Potentiation by aminopeptidase P of blood pressure response to bradykinin. | Kitamura, S., et al. 1995. Br J Pharmacol. 114: 6-7. PMID: 7712030
- Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. | Prechel, MM., et al. 1995. J Pharmacol Exp Ther. 275: 1136-42. PMID: 8531074
- Influence of several peptidase inhibitors on the pro-inflammatory effects of substance P, capsaicin and collagenase. | Damas, J., et al. 1996. Naunyn Schmiedebergs Arch Pharmacol. 354: 662-9. PMID: 8938667
- Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation. | Erşahin, C. and Simmons, WH. 1997. J Cardiovasc Pharmacol. 30: 96-101. PMID: 9268227
- Intravascular and interstitial degradation of bradykinin in isolated perfused rat heart. | Dendorfer, A., et al. 1997. Br J Pharmacol. 122: 1179-87. PMID: 9401784
Inhibitor of:
Aminopeptidase P, and Protease.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Apstatin, 1 mg | sc-201309 | 1 mg | $132.00 |